L-DOX

DOXOrubicin Hydrochloride Liposome injection is indicated for the treatment of:
Ovarian Cancer
: DOXOrubicin Hydrochloride Liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy
... Read more
DOXOrubicin Hydrochloride Liposome injection is indicated for the treatment of:
Ovarian Cancer
: DOXOrubicin Hydrochloride Liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.
AIDS-Related Kaposi’s Sarcoma
: It is indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy.
Multiple Myeloma
: For the treatment of patients with multiple myeloma in combination with Bortezomib, who have not previously received Bortezomib and have received at least one prior therapy.
Also indicated for the monotherapy for patients with metastatic breast cancer, where patient is associated with increased cardiac risk with conventional DOXOrubicin Hydrochloride Liposome.

Increased risk of getting an infection
Breathlessness and looking pale
Tiredness and weakness
Feeling or being sick
Inflammation of the lining of the mouth, throat, food pipe and stomach
Soreness, redness and peeling of your hands and feet
Loss of appetite
Hair loss
Diarrhea or constipation
Pain in different parts of the body
Skin changes

Cardiomyopathy
: DOXOrubicin Hydrochloride Liposome Hydrochloride can cause myocardial damage, including acute left ventricular failure.
Infusion-Related Reactions
: Flushing, shortness of breath, facial swelling, headache, chills, chest pain, back pain, tightness in the chest and throat, fever, tachycardia, pruritus, rash, cyanosis, syncope, bronchospasm, asthma, apnea, and hypotension.
Hand-Foot Syndrome (HFS)
: HFS or other skin toxicity required discontinuation of DOXOrubicin Hydrochloride Liposome injection in 4.2% of patients.
Secondary Oral Neoplasms
: Secondary oral cancers, primarily squamous cell carcinoma, have been reported from post-marketing experience in patients with long-term (more than one year) exposure to DOXOrubicin Hydrochloride Liposome injection.
Embryo-Fetal Toxicity
: Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during and for 6 months after treatment with DOXOrubicin Hydrochloride Liposome injection.

Doxorubicin is a cytotoxic anthracycline antibiotic isolated from Streptomyces Peucetius var. Caesius. Doxorubicin Hydrochloride Liposome injection is Doxorubicin Hydrochloride encapsulated in Stealth Liposomes for intravenous administration. Greater than 90 % of the drug is encapsulated in the stealth Liposomes.
The active ingredient of Doxorubicin Hydrochloride Liposome Injection is Doxorubicin Hydrochloride. The mechanism of action of Doxorubicin Hydrochloride is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and induction of mutagenesis and chromosomal aberrations.
Doxorubicin Hydrochloride Liposome injection displays linear pharmacokinetics over the range of 10-20 mg/m2 . Disposition occurs in two phases after administration of Doxorubicin Hydrochloride Liposome injection, with a relatively short first phase (5 hours) and a prolonged second phase (55 hours) which accounts for majority of the area under the curve (AUC).
Distribution
: Direct measurement of Doxorubicin Hydrochloride Liposome injection shows that at least 90% of the drug (the assay used cannot quantify less than 5-10% free doxorubicin) remains Liposome-encapsulated during circulation.
Metabolism
: Doxorubicinol, the major metabolite of Doxorubicin, was detected at concentrations of 0.8 to 26.2 ng/mL in the plasma of patients who received 10 or 20 mg/m 2 Doxorubicin Hydrochloride Liposome injection
Excretion
: The plasma clearance of total Doxorubicin Hydrochloride Liposome injection was 0.041 L/h/m2 at a dose of 20 mg/m2 . Following administration of Doxorubicin Hydrochloride, the plasma clearance of doxorubicin is 24 to 35 L/h/m2 .